PPA
PTCT icon

Parametric Portfolio Associates’s PTC Therapeutics PTCT Stock Holding History

Parametric Portfolio Associates’s Portfolio PTCT Stock Details PTCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		$2.09M Sell
55,935
-38,475
-41% -$1.48M ﹤0.01% 2405
2021
Q4 		$3.76M Buy
94,410
+7,548
+9% +$289K ﹤0.01% 2057
2021
Q3 		$3.23M Buy
86,862
+14,914
+21% +$613K ﹤0.01% 2130
2021
Q2 		$3.04M Buy
71,948
+8,177
+13% +$350K ﹤0.01% 2179
2021
Q1 		$3.02M Buy
63,771
+9,043
+17% +$537K ﹤0.01% 2520
2020
Q4 		$3.34M Buy
54,728
+5,087
+10% +$300K ﹤0.01% 2341
2020
Q3 		$2.32M Buy
49,641
+5,480
+12% +$270K ﹤0.01% 2413
2020
Q2 		$2.24M Sell
44,161
-1,182
-3% -$58.1K ﹤0.01% 2426
2020
Q1 		$2.02M Buy
45,343
+6,949
+18% +$350K ﹤0.01% 2371
2019
Q4 		$1.84M Buy
38,394
+1,066
+3% +$45.3K ﹤0.01% 2742
2019
Q3 		$1.26M Buy
37,328
+3,620
+11% +$158K ﹤0.01% 2905
2019
Q2 		$1.52M Sell
33,708
-7,814
-19% -$309K ﹤0.01% 2830
2019
Q1 		$1.56M Sell
41,522
-898
-2% -$30.1K ﹤0.01% 2793
2018
Q4 		$1.46M Buy
42,420
+16,029
+61% +$576K ﹤0.01% 2784
2018
Q3 		$1.24M Sell
26,391
-1,398
-5% -$57.8K ﹤0.01% 2969
2018
Q2 		$937K Buy
27,789
+720
+3% +$22.5K ﹤0.01% 3091
2018
Q1 		$732K Sell
27,069
-51
-0.2% -$1.29K ﹤0.01% 3168
2017
Q4 		$452K Buy
27,120
+381
+1% +$6.45K ﹤0.01% 3382
2017
Q3 		$535K Sell
26,739
-21,265
-44% -$416K ﹤0.01% 3385
2017
Q2 		$880K Buy
48,004
+7,788
+19% +$105K ﹤0.01% 3048
2017
Q1 		$396K Sell
40,216
-42,457
-51% -$514K ﹤0.01% 3315
2016
Q4 		$902K Buy
82,673
+38,996
+89% +$409K ﹤0.01% 2897
2016
Q3 		$612K Sell
43,677
-9,507
-18% -$77.3K ﹤0.01% 3076
2016
Q2 		$373K Buy
53,184
+34,112
+179% +$250K ﹤0.01% 3351
2016
Q1 		$123K Sell
19,072
-177,846
-90% -$3.09M ﹤0.01% 3835
2015
Q4 		$6.38M Buy
196,918
+178,349
+960% +$5.25M 0.01% 1151
2015
Q3 		$496K Buy
18,569
+3,904
+27% +$167K ﹤0.01% 2726
2015
Q2 		$706K Buy
14,665
+2,226
+18% +$130K ﹤0.01% 3030
2015
Q1 		$757K Buy
12,439
+579
+5% +$35.3K ﹤0.01% 2989
2014
Q4 		$614K Buy
11,860
+905
+8% +$39.8K ﹤0.01% 3145
2014
Q3 		$482K Buy
+10,955
New +$343K ﹤0.01% 3229

Other funds holding PTCT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
CCM
Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return

Parametric Portfolio Associates's PTCT Position: Q1 2022 in Review

Parametric Portfolio Associates reduced its PTC Therapeutics (PTCT) stake by 41% in Q1 2022, selling an estimated $1.48M and leaving 55,935 shares worth $2.09M. The position accounts for ﹤0.01% of the portfolio, ranked #2405.

Parametric Portfolio Associates first reported a position in PTCT in Q3 2014 and has held it in 31 quarters since. The position peaked at $6.38M in Q4 2015. 185 funds tracked by Wall St. Rank hold PTCT as of Q1 2022.

  • Parametric Portfolio Associates held 55,935 shares of PTC Therapeutics worth $2.09M as of Q1 2022.
  • Parametric Portfolio Associates sold 38,475 PTC Therapeutics shares in Q1 2022, an estimated $1.48M.
  • PTC Therapeutics made up ﹤0.01% of Parametric Portfolio Associates's portfolio in Q1 2022, its #2405 holding.
  • Parametric Portfolio Associates first reported a position in PTC Therapeutics in Q3 2014 and has held it in 31 quarters since.
  • Parametric Portfolio Associates's PTC Therapeutics position peaked at $6.38M in Q4 2015.
  • 185 funds tracked by Wall St. Rank held PTC Therapeutics as of Q1 2022.

Based on Parametric Portfolio Associates's 13F filing for Q1 2022, filed 16 May 2022.